On Mary 14, 2026, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026. The company continues preparations for an upcoming Phase 2 clinical trial of EB06 (anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo. Edesa has selected the clinical research company and outreach to potential clinical sites and investigators has begun. We continue to anticipate the trial initiating (in Canadian investigational sites) in mid-2026, subject to regulatory approval. Earlier this year, Edesa announced positive results for paridiprubart (EB05) that continued to show a mortality benefit in patients suffering from acute respiratory distress syndrome (ARDS). The company is planning to meet with regulatory authorities to discuss next steps for that program.
